Pipeline - GenrAb

Lead Candidate

A FULLY HUMAN NEUROPROTECTIVE ANTIBODY

Innovative AGS Technology
Identified using the AGS technology confirming critical disease-associated antibody somatic hypermutations
Neuronal Specificity
Exhibits specific binding to neuronal cells and tissues in both animals and humans
Preclinical Efficacy
Demonstrated a consistent reduction in disability within preclinical models of neurologic disease at GenrAb and in a blinded third-party study
Target Identification and Verification
Unique target identified and verified; mechanistic studies underway
Broad Neuroprotective Impact
Broad neuroprotective capabilities, with proof-of-concept in MS and planned expansion into ALS
Patent Achievement
A US patent has been issued for TGM-010 mAb and its fragments; claims for indicational therapeutic use will be pursued next

GenrAb’s Growing Pipeline

Pipeline

Stage 1
Screening for AGS sequence and neuronal binding
Stage 2
In-vitro efficacy and toxicity analysis

Stage 2
Stage 3
Efficacy validated in multiple preclinical models
Stage 4
Identify and verify molecular target

Stage 4
Stage 5
Determine target biology and therapeutic MoA
Stage 6
mAbs optimized for dosing

Stage 6